GlassScriptPhysician profile
Erin Forster
NPI 1972894376
$788,035.11
in general payments reported to CMS, 2019-2025
16 companies · $193K in 2025
The $193K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87K · 2020: $20K · 2021: $35K · 2022: $126K · 2023: $162K · 2024: $164K · 2025: $193K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $363K · Travel and Lodging: $86K · Consulting Fee: $58K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $362,608.43 |
| Travel and Lodging | $86,149.55 |
| Consulting Fee | $58,270.83 |
| Food and Beverage | $12,349.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $407,022.83 | 2019-2025 | |
| Janssen Biotech, INC. | $150,098.89 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $85,648.69 | 2020-2023 | |
| Genentech, INC. | $60,903.51 | 2025 | |
| Janssen Scientific Affairs, LLC | $49,915.15 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $16,537.89 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $8,221.70 | 2019-2025 | Entyvio |
| Celgene Corporation | $7,397.63 | 2021-2023 | Zeposia |
| Janssen Research & Development, LLC | $1,535.36 | 2022 | |
| Lilly USA, LLC | $305.51 | 2023-2025 | Omvoh |
| Ambu INC. | $255.58 | 2020-2021 | |
| Conmed Corporation | $105.47 | 2019 | |
| Daiichi Sankyo INC. | $38.50 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.90 | 2020-2021 | |
| Gilead Sciences, INC. | $14.50 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Forster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.